LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Brokerage Reports
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 181 - 193 ( 193 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Encouraging Analyst Day Takeaways - Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Analyst Meeting: Sales Force To Drive Growth, Though Company Strengths Run Deep As Well
Provider: The Benchmark Company
Analyst: WALD J
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Strong 12% Revenue Growth in the Quarter and Raising Revenue Guidance; Increasing Price Target to $10
Provider: The Benchmark Company
Analyst: WALD J
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Revenue Beat & Raise Offset by Near- Term Margin Headwinds; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
3Q Preview: Possibility for Raised 2013 Guidance on InaVein Acq.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Established Company, Attractive Risk- Reward; Initiating with a Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C